CA-CAVLI-WIRELESS
26.3.2024 10:21:33 CET | Business Wire | Press release
Cavli Wireless, a pioneer in the IoT solutions landscape, is all set to announce its flagship 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024. The event, held at the NürnbergMesse GmbH, Nürnberg, Germany, from April 9 to 11 in Hall 3, Booth 3-311. Embedded World event is known for being the largest trade fair for Embedded technology, showcasing the latest and greatest in electronic systems, distributed intelligence, IoT, energy efficiency, and more. The event represents the premier stage for global innovators like Cavli Wireless to showcase the innovative CQM220 to the world.
The CQM220 is the flagship 5G RedCap cellular IoT module from Cavli Wireless, compatible with 3GPP release 17 standards, specifically designed for advanced IoT and M2M applications. It delivers robust data bandwidth, reaching up to 226Mbps in downlink and 121Mbps in uplink, facilitating rapid and efficient data transfer. Available in LGA, PCIe Gen2, and M.2 form factors, the CQM220 ensures broad compatibility and flexibility across various industrial applications. Its optional integrated eSIM offers global connectivity through the Cavli Hubble Device and Connectivity management platform, making it a versatile solution for international deployment.
Moreover, the CQM220's optional integrated GNSS feature positions it as an ideal candidate for precise tracking applications, essential in sectors like Asset Tracking and Vehicular Telemetry Systems. Accompanied by a Linux-based OpenSDK, the module allows for application-specific coding directly on the device, eliminating the need for an external host MCU. This capability, combined with its high data throughput and global operability, makes the CQM220 an optimal choice for next-generation applications that demand speed, accuracy, and worldwide functionality.
The CQM220 module is set to supercharge a range of industries with its advanced connectivity. In Industry 4.0, the module's high data throughput, and integrated GNSS make it a linchpin for smart factories, facilitating real-time monitoring and control of machinery, and predictive maintenance, thereby enhancing efficiency and reducing downtime. For Smart City initiatives, the CQM220's global connectivity and robust bandwidth support the deployment of smart grids, intelligent transportation systems, and public safety networks, contributing to more efficient and responsive urban environments. In asset tracking, the precision of the integrated GNSS and the module's widespread connectivity ensure accurate, real-time location tracking of goods and equipment across borders, which is crucial for logistics, fleet management, and theft prevention. Across these applications, the CQM220 empowers industries to harness the full potential of seamless global connectivity, driving innovation and operational excellence.
The Cavli Hubble Stack further enhances the capabilities of the CQM220 by introducing remote diagnosis, monitoring, and debugging of the module through Hubble Lens, an advanced component of the Cavli Hubble IoT connectivity & modem management platform. This feature eliminates the necessity for physical intervention, simplifying the expansion of IoT solutions. Through strategic alliances with operators worldwide, Cavli has established a substantial presence, delivering unparalleled connectivity solutions that set new standards in service quality and cost-effectiveness.
John Mathew, the CEO and the Chief Technology Architect of Cavli Wireless, remarked, "Unveiling the CQM220 at Embedded World 2024 marks a pivotal point for our company. Our continuous commitment to superior performance and creativity in the field of intelligent cellular connections has culminated in the creation of this durable 5G RedCap module. It is characterized by its dependability, effectiveness, and the ability to provide uninterrupted connectivity worldwide. These features are the core aspects of the CQM220 and serve to set apart both the product and Cavli Wireless in the bustling market."
With the unveiling of the CQM220 at Embedded World 2024, Cavli Wireless reiterates its dedication to providing cost-effective, uninterrupted, and superior cellular IoT solutions. We encourage you to engage with our solution specialists to explore the ways the CQM220 can enhance your upcoming project. Embark on your path to dependable and effective connectivity with Cavli.
About Cavli Wireless
Cavli Wireless is a cellular IoT module manufacturer that combines IoT connectivity and data management into one platform. Cavli designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite application development processes. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable global data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
The Embedded World Exhibition & Conference is a global platform for the embedded systems community, where professionals from around the world can connect and share knowledge. The event offers insights into the entire world of embedded systems, including hardware, software, tools, and services. It features a high-quality transfer of knowledge through top-class speakers, expert panels, and exhibitor forums.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326234488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom